Novo Nordisk Limits Supply of Wegovy Amid High Demand
Novo Nordisk is limiting the supply of low doses of obesity medication Wegovy in the U.S. due to high demand. The company is still supplying limited quantities of the drug to wholesalers for distribution to retail pharmacies. Wegovy was approved by the FDA in 2021 as a weight management treatment medication and belongs to a class of drugs called GLP-1 agonists. The drug has become popular in the weight loss industry, and endorsements by celebrities on social media have fueled shortages nationwide.